August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
January 2023 in “National journal of physiology, pharmacy and pharmacology” Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
8 citations
,
May 2016 in “Indian Journal of Pharmacology” Finasteride and dutasteride can cause severe, lasting side effects.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
24 citations
,
July 1983 in “Clinical and Experimental Dermatology” Tigason improved hair growth in a boy with monilethrix without side effects.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
23 citations
,
October 2012 in “ChemistryOpen” Probe detects finasteride with high selectivity and low detection limit.
14 citations
,
November 2014 in “European journal of medicinal chemistry” Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
20 citations
,
September 2013 in “Anti-Cancer Drugs” PTH-CBD could help prevent and treat hair loss caused by chemotherapy in mice.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
June 2025 in “Deleted Journal” Selamectin effectively cured the cats' infestation.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
April 2023 in “Medicina Clínica (english Edition)”
2 citations
,
November 2022 in “Skin research and technology” 5% topical minoxidil improves hair density and quality in monilethrix patients.
July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers a free, effective solution to eliminate aflatoxin and cancer, improving health and life expectancy.
September 2012 in “The Egyptian Journal of Histology” Flutamide caused damage to male rat reproductive organs and may affect fertility.
5 citations
,
January 2018 The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.
11 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
12 citations
,
August 2017 in “Pharmaceutical medicine” Most doctors know the thrombosis risk with Cyproterone/Ethinylestradiol, but some lack details on less common risks and patient instructions; educational materials are underused but useful.
March 2022 in “Journal of The American Academy of Dermatology” November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
May 2025 in “Reactions Weekly”